Cargando…
Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced “Eosinophilic Fasciitis-Like” Case and a Review of the Literature
Immune checkpoint inhibitors are a promising new therapeutic strategy in oncology that aims to eliminate cancer cells by enhancing patients' immune response against tumor antigens. Despite their beneficial effects, immune checkpoint inhibitors are also responsible for a plethora of autoimmune m...
Autores principales: | Salamaliki, Christina, Solomou, Elena E., Liossis, Stamatis-Nick C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695772/ https://www.ncbi.nlm.nih.gov/pubmed/33067734 http://dx.doi.org/10.1007/s40744-020-00246-z |
Ejemplares similares
-
Eosinophilic Fasciitis following Checkpoint Inhibitor Therapy with Pembrolizumab
por: Zampeli, Evangelia, et al.
Publicado: (2021) -
B cells tell scleroderma fibroblasts to produce collagen
por: Daoussis, Dimitrios, et al.
Publicado: (2013) -
The Role of B Cells in Scleroderma Lung Disease Pathogenesis
por: Liossis, Stamatis-Nick C., et al.
Publicado: (2022) -
Eosinophilic fasciitis difficult to differentiate from scleroderma: A case report
por: Lan, Tian-Yi, et al.
Publicado: (2023) -
How to Make the Right Diagnosis in Neutropenia
por: Solomou, Elena E., et al.
Publicado: (2021)